Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Hemay005 in moderate to severe ulcerative colitis
CTR20221945Phase 2Active
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mufemilast in autoimmune colitis, sponsored by Hemay Pharmaceutical Technology. Started Mar 2023; status: active.
02
Drugs
mufemilast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20221945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221945.